Abstract:Introduction: Human myasthenia gravis (MG) is an autoimmune disorder of the neuromuscular system. Experimental autoimmune myasthenia gravis (EAMG) is a well-established animal model for MG that can be induced by active immunization with the Torpedo californica-derived acetylcholine receptor (AChR). Due to the expensive cost of purifying AChR from Torpedo californica, the development of an easier and more economical way of inducing EAMG remains critically needed. Material and methods: Full-length cDNA of the human skeletal muscle AChR α1 subunit was obtained from TE671 cells. The DNA fragment encoding the extracellular domain (ECD) was then amplified by polymerase chain reaction (PCR) and inserted into pET-16b. The reconstructed plasmid was transformed into the host strain BL21(DE3)pLysS, which was derived from Escherichia coli. Isopropyl-β-D-thiogalactopyranoside (IPTG) was used to induce the expression of the N-terminal ECD. The produced protein was purified with immobilized Ni(2+) affinity chromatography and refolded by dialysis. Results: The recombinant protein was efficiently refolded to soluble active protein, which was verified by ELISA. After immunization with the recombinant ECD, all rats acquired clinical signs of EAMG. The titer of AChR antibodies in the serum was significantly higher in the EAMG group than in the control group, indicating successful induction of EAMG. Conclusions: We describe an improved procedure for refolding recombinant ECD of human muscle AChR. This improvement allows for the generation of large quantities of correctly folded recombinant ECD of human muscle AChR, which provides for an easier and more economical way of inducing the animal model of MG.

Model of Passive Transferred Experimental Myasthenia Gravis Inducing on Sprague-Dawley Rats

Induce Experimental Autoimmune Myasthenia Gravis on Rats by Passive Transfer Acetylcholine Receptor Monoclonal Antibody

Establishment of the animal model of experimental autoimmune myositis

Establishment of a Mouse Model of Experimental Autoimmune Myasthenia Gravis

Development of an improved animal model of experimental autoimmune myositis.

Susceptible Mechanisms of Extraocular Muscles in the Passive Transferred Experimental Myasthenia Gravis Rats

Institution of Model of Myasthenia Gravis in Transgenic Mice

Establishment of Animal Models of Experimental Autoimmune Myositis

A novel model of central nervous system involvement in myasthenia gravis

The Involving Proofs of Extraocular Muscle in Passive Transferred Experimental Myasthenia Gravis in Rats

Artificial Construction of Human Pathogenic Autoantibody in Myasthenia Gravis

The Effect of CD3-specific Monoclonal Antibody on Treating Experimental Autoimmune Myasthenia Gravis.

Improved methodology to obtain large quantities of correctly folded recombinant N-terminal extracellular domain of the human muscle acetylcholine receptor for inducing experimental autoimmune myasthenia gravis in rats

A Study of Magnetic Motor Evoked Potentials in the Central Nervous System Dysfunction Model of Myasthenia Gravis

PATHOGENICITY AND SEQUENCE ANALYSIS OF A MOUSE MONOCLONAL ANTIBODY AGAINST HUMAN ACETYLCHOLINE RECEPTOR IN MYASTHENIA GRAVIS

Research on Morphological Changes of End Plates in Diaphragm of Experimental Autoimmune Myasthenia Gravis Rats

The Found of Animal Models of Experimental Autommune Myasthenis Gravis

Construction of a myasthenia gravis model by immunizing mice with gene vaccine pcDNA-AChR_(α211)

The mouse passive‐transfer model of MuSK myasthenia gravis: disrupted MuSK signaling causes synapse failure

Experimental autoimmune myositis model induced by pure myosin of rabbit

Pathogenesis of Myasthenia Gravis in Transgenic Mouse Induced with Torpedo Acetylcholine Receptor